RESUMO
Hybrid medicines are defined as medicines that do not fill generic medicines' definition, forming a medicines group that stands half-way between reference medicinal products and generic medicines. The term "hybrid" was introduced in France in 2018, but the concept has existed for some fifteen years in Community legislation. The aim of this work is to expose hybrid medicines' legal framework, in Europe and in France. Hybrid medicines' European legal framework specifies in a guide of the European Medicines Agency, marketing authorization procedures that can be used for hybrid medicines, and what is required for marketing authorization applications. In France, a register of hybrid medicines' groups has been created, and registration procedures were specified in a decree at the end of 2019. Legal texts also underlined that substitution within hybrid medicines' group would be possible for some specific medical cases. Decrees specifying hybrid medicines' groups list and specific medical cases allowing substitution, are not appeared yet at the end of February 2021. Moreover, some elements have never been raised, particularly medical and economic assessment modalities.
Assuntos
Medicamentos Genéricos , Marketing , Europa (Continente) , FrançaRESUMO
Over recent years, the psychiatric sector has endeavoured to develop community-based care. Paradoxically, the number of compulsory hospitalisations is increasing. At the same time, the legal framework is evolving and measures relating to the deprivation of liberty in the context of psychiatric care have given rise to extensive guidelines. The work of the French National Health Authority represents, in this context, a certain continuity, with regard to the legal, ethical and social discussions around restriction of liberty practices within psychiatric units. The main focus is on the prevention and management of violent outbursts.
Assuntos
Internação Compulsória de Doente Mental/legislação & jurisprudência , Transtornos Mentais/enfermagem , Unidade Hospitalar de Psiquiatria/legislação & jurisprudência , Violência/prevenção & controle , Redes Comunitárias/ética , Redes Comunitárias/legislação & jurisprudência , Consenso , Ética Médica , França , Fidelidade a Diretrizes , Humanos , Transtornos Mentais/psicologia , Defesa do Paciente/legislação & jurisprudência , Isolamento de Pacientes/legislação & jurisprudência , Isolamento de Pacientes/psicologia , Unidade Hospitalar de Psiquiatria/ética , Enfermagem Psiquiátrica/legislação & jurisprudência , Restrição Física/legislação & jurisprudência , Restrição Física/psicologia , Medição de Risco/legislação & jurisprudência , Esquizofrenia/diagnóstico , Esquizofrenia/enfermagem , Psicologia do Esquizofrênico , Violência/éticaRESUMO
While the Ministry of Health has been communicating for several months about the launch of the reform of the nursing profession, work finally began in mid-2023 in the field of practice, to efine the new perimeters to be covered for the profession of tomorrow. At the same time, the move towards university-based initial nursing training, which began in 2009, is continuing, with discussions starting at the end of 2023 on educational engineering, selection procedures, placements, student rights, the fundamentals of research teaching, etc. Between increasing skills and the associated responsibilities, and establishing a disciplinary field, the development of the profession is part of a gradual historical construction.
Assuntos
Educação em Enfermagem , Humanos , França , Educação em Enfermagem/organização & administraçãoRESUMO
In addition to the Code of Ethics, the legal framework protecting transgender people in their medical care is very limited. The conclusions of different reports or opinions, notably from the National Consultative Commission on Human Rights, show that transgender individuals are often faced with a great lack of understanding on the part of health care providers. This ultimately leads to discrimination, and therefore to abuse. Improving their care is important in order to limit this discrimination and, consequently, the factors of over-victimization.
Assuntos
Pessoas Transgênero , Humanos , Direitos Humanos , Pessoal de SaúdeRESUMO
OBJECTIVE: The objective was to take stock of the regulation of clinical trials in Mali. MATERIAL AND METHODS: This was a descriptive cross-sectional study carried out of the September 1 to December 15, 2019. It consisted of a literature search and a survey in research centers, ethics committees and regulatory structures in Mali. RESULTS: In 2019, there were 15 clinical trials authorized and conducted by three research centers, including 12 vaccines and 3 drugs trials all approved by an ethics committee. The legal framework for clinical trials is governed in Mali by two texts, one legislative and the other regulatory. They provide for the authorization, suspension or prohibition of biomedical research by the minister in charge of Health. The shortcomings identified relate to the low recovery and lack of evaluation of pharmacovigilance data, the scarcity of site inspections and especially the absence of a technical committee for regulatory evaluation of files at the Pharmacy and Medicines Department (DPM). CONCLUSION: The strengthening of the legal framework is, more than ever, necessary to ensure the protection of the rights, safety and well-being of research subjects in a context of increasing relocation of clinical trials to our countries.
OBJECTIF: L'objectif était de réaliser l'état des lieux de la réglementation des essais cliniques au Mali. MATÉRIEL ET MÉTHODES: Il s'agissait d'une étude transversale descriptive réalisée du 1er septembre au 15 décembre 2019. Elle a consisté en une recherche documentaire et une enquête de terrain dans les centres de recherche, les comités d'éthique et les structures règlementaires du Mali. RÉSULTATS: En 2019, il y a eu 15 essais cliniques autorisés et réalisés par trois centres de recherche, dont 12 vaccinaux et 3 médicamenteux tous approuvés par un comité d'éthique. Le cadre juridique des essais cliniques est régi au Mali par deux textes dont l'un législatif et l'autre réglementaire. Ils prévoient l'autorisation, la suspension ou l'interdiction de la recherche biomédicale par le ministre en charge de la santé. Les insuffisances recensées sont relatives à la faible remontée et au manque d'évaluation des données de pharmacovigilance, la rareté des inspections des sites et surtout l'absence de comité technique d'évaluation règlementaire des dossiers à la Direction de la Pharmacie et du Médicament (DPM). CONCLUSION: Le renforcement du cadre juridique est, plus que jamais, nécessaire pour assurer la protection des droits, la sécurité et le bien-être des sujets de recherche dans un contexte de délocalisation croissante des essais cliniques vers nos pays.
RESUMO
Objectif: L'objectif était de réaliser l'état des lieux de la réglementation des essais cliniques au Mali. Matériel et Méthodes: Il s'agissait d'une étude transversale descriptive réalisée du 1er septembre au 15 décembre 2019. Elle a consisté en une recherche documentaire et une enquête de terrain dans les centres de recherche, les comités d'éthique et les structures règlementaires du Mali. Résultats: En 2019, il y a eu 15 essais cliniques autorisés et réalisés par trois centres de recherche, dont 12 vaccinaux et 3 médicamenteux tous approuvés par un comité d'éthique. Le cadre juridique des essais cliniques est régi au Mali par deux textes dont l'un législatif et l'autre réglementaire. Ils prévoient l'autorisation, la suspension ou l'interdiction de la recherche biomédicale par le ministre en charge de la santé. Les insuffisances recensées sont relatives à la faible remontée et au manque d'évaluation des données de pharmacovigilance, la rareté des inspections des sites et surtout l'absence de comité technique d'évaluation règlementaire des dossiers à la Direction de la Pharmacie et du Médicament (DPM). Conclusion: Le renforcement du cadre juridique est, plus que jamais, nécessaire pour assurer la protection des droits, la sécurité et le bien-être des sujets de recherche dans un contexte de délocalisation croissante des essais cliniques vers nos pays
Objective: The objective was to take stockof the regulation of clinical trials in Mali. Material and Methods: This was a descriptive cross-sectional study carried out of the September 1 to December 15, 2019. It consisted of a literature search and a survey in research centers, ethics committees and regulatory structures in Mali. Results: In 2019, there were 15 clinical trials authorized and conducted by three research centers, including 12 vaccines and 3 drugs trials all approved by an ethics committee. The legal framework for clinical trials is governed in Mali by two texts, one legislative and the other regulatory. They provide for the authorization, suspension or prohibition of biomedical research by the minister in charge of Health. The shortcomings identified relate to the low recovery and lack of evaluation of pharmacovigilance data, the scarcity of site inspections and especially the absence of a technical committee for regulatory evaluation of files at the Pharmacy and Medicines Department (DPM). Conclusion: The strengthening of the legal framework is, more than ever, necessary to ensure the protection of the rights, safety and well-being of research subjects in a context of increasing relocation of clinical trials to our countries